Please login to the form below

Not currently logged in
Email:
Password:

kinase inhibitor

This page shows the latest kinase inhibitor news and features for those working in and with pharma, biotech and healthcare.

Biogen picks up another drug from wide-ranging Ionis alliance

Biogen picks up another drug from wide-ranging Ionis alliance

Among others in late-stage development are AB Sciences’ tyrosine kinase inhibitor masitinib, which was turned down by the CHMP in April at its first attempt for EU approval, and Orion

Latest news

  • BMS CEO tackles investor ‘frustrations’ on immuno-oncology BMS CEO tackles investor ‘frustrations’ on immuno-oncology

    BMS was the pathfinder for the checkpoint inhibitor market with its CTLA4 inhibitor Yervoy (ipilimumab) and PD-1 blocker Opdivo (nivolumab), However, it has since lost ground to rival Merck ... inhibitor Bavencio (avelumab) – both given in tandem with

  • Merck’s Bavencio joins first-line kidney cancer face-off Merck’s Bavencio joins first-line kidney cancer face-off

    The JAVELIN Renal 101 study reported at this week’s ESMO conference paired Merck’s immuno-oncology drug Bavencio (avelumab) with Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib), and revealed a ... inhibitor and TKI has emerged as an “early

  • A look ahead to key trial readouts at ESMO A look ahead to key trial readouts at ESMO

    101 study, the first time that a checkpoint inhibitor has shown an increase in progression-free survival (PFS) when combined with a tyrosine kinase inhibitor – in this case Pfizer’s Inlyta ... for its MAGE-A10-targeting cell therapy in non-small cell

  • FDA approval gained, Pfizer sets sights on first-line NSCLC market FDA approval gained, Pfizer sets sights on first-line NSCLC market

    Vizimpro could challenge Tagrisso, survival data will be key. Pfizer’s gruelling trek to bring EGFR inhibitor dacomitinib to market has finally paid off, with the FDA approving it as a ... The second-generation EGFR tyrosine kinase inhibitor has been

  • BMS psoriasis drug hits the mark in phase II BMS psoriasis drug hits the mark in phase II

    The phase II trial of tyrosine kinase 2 (Tyk2) inhibitor BMS-986165 showed a level of efficacy that was greater than other oral therapies for people with the skin disorder and ... JAK inhibitor class – which act via the same pathway but haven’t been

More from news
Approximately 0 fully matching, plus 144 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    The headline value contains significant sales milestones linked to performance of Impact's lead phase III stage asset fedratinib, an oral JAK2 kinase inhibitor in development for the treatment of myelofibrosis ... Acquisition company -  remaining 90%. 9

  • Deal Watch September 2016 Deal Watch September 2016

    No financial terms were disclosed. Genentech signed an exclusive licence [global excluding South Korea] with Hanmi Pharmaceutical to develop and market HM95573, a pan-RAF inhibitor. ... 1, 000+. Hanmi / Genentech. Licence. HM95573, a selective

  • Deal Watch June 2016 Deal Watch June 2016

    acquisition assets. 350. CrystalGenomics/ Aptose Biosciences. CG026806 inhibitor of Bruton's tyrosine kinase, FMS-like tyrosine kinase 3 and Aurora kinases (preclinical). † ... acquisition company. 105. Nektar Therapeutics/ Daiichi Sankyo Europe.

  • Deal Watch May 2016 Deal Watch May 2016

    Paying a 55% premium at $99.25 per share, the acquisition brings crisaborole, a topical PDE4 inhibitor for mild to moderate atopic dermatitis (eczema) with estimated peak sales of $2bn. ... 282. Carna Biosciences/ ProNAi Therapeutics. Licence. $0.9m

  • Pharma deals in September 2015 Pharma deals in September 2015

    Purdue licensed VM Pharma's allosteric selective tropomyosin receptor kinase A (TrkA) inhibitor programme for chronic pain. ... Collaboration - public private partnership. 220. VM Pharma. Purdue Pharma. VM902A a signalling protein tropomyosin receptor

More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics